查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999352

自动化和封闭式细胞治疗处理系统市场：全球市场按产品类型、技术、工艺类型、应用和最终用户分類的预测——2026-2032年

Automated & Closed Cell Therapy Processing Systems Market by Product Type, Technology, Process Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自动化密封细胞治疗处理系统市场价值将达到 12.4 亿美元，到 2026 年将成长至 14.3 亿美元，到 2032 年将达到 36.3 亿美元，复合年增长率为 16.49%。

主要市场统计数据
基准年 2025 12.4亿美元
预计年份：2026年 14.3亿美元
预测年份 2032 36.3亿美元
复合年增长率 (%) 16.49%

简要概述自动化和密封处理如何改变细胞治疗操作、监管预期和临床准备。

随着自动化和封闭式流程解决方案从小众实验室工具发展成为临床计画的基础架构，细胞治疗的治疗环境正在迅速演变。平台工程的进步，以及对产品品质一致性和减少人工操作流程日益增长的需求，使得自动化和封闭式系统不再只是为了方便操作，而是成为实现可扩展治疗方法的战略要素。临床医生和生产负责人越来越重视流程标准化、污染控制和可追溯性，并将这些视为规划细胞治疗产品线的关键要素。

对细胞治疗製程的主要係统性变革进行整体情况，优先考虑自动化、污染控制、互通性和长期临床扩充性。

近年来，随着研发人员、监管机构和支付方将重点转向可靠性、扩充性和患者安全，细胞治疗生态系统发生了变革性变化。首先，人们越来越重视透过自动化来降低变异性。人工交接和开放式操作方式日益被视为影响疗效和一致性的风险因子。其次，封闭式处理架构因其能更有效地控制污染并提高复杂供应链的可追溯性而备受关注。

该评估旨在评估近期关税变化和贸易政策趋势对供应商策略、采购风险管理和区域供应链韧性的影响。

近期影响关税和贸易的政策决定可能会对全球加工设备的资本投资计画和供应商策略产生重大影响。关税调整会改变进口设备和耗材的相对成本竞争力，进而影响新创公司和成熟製造商的采购决策。因此，设备供应商正在重新审视製造地、供应商合约和零件采购，以降低跨境税收变化带来的风险。

详细的細項分析表明，产品类型、临床应用、分离技术、最终用户和个人製程能力如何决定采购和验证的优先事项。

稳健的细分观点阐明了不同的产品架构、临床应用、隔离技术、最终用户和流程类型如何影响采购决策和营运优先顺序。产品类型区分了整合多个单元操作的全自动系统和主要用于降低污染风险和人工接触的封闭式系统，两者均具有不同的验证途径和设施要求。基于应用的细分区分了异体疗法（包括造血干细胞疗法、间质干细胞疗法和自然杀手细胞疗法）和自体疗法（包括CAR-T细胞疗法、造血干细胞疗法和间质干细胞疗法），每种应用都有其独特的处理能力、无菌性和控制历史要求。

区域趋势和部署策略解释了北美和南美、欧洲、中东和非洲以及亚太地区的市场如何影响供应商的方法和临床实施。

区域趋势正以不同的方式影响医疗器材的采纳路径、供应商策略和监管预期。在美洲，创新公司和成熟製造商在强调流程控制和临床安全证据的法规环境下并存，这促进了简化合规流程和加速院内生产的系统的早期应用。资金筹措环境和临床卓越中心的集中也为医疗器材供应商和临床开发商之间的伙伴关係提供了支持。

竞争力和供应商差异化由技术创新、验证服务、耗材策略和策略临床伙伴关係关係驱动。

处理系统市场的竞争格局取决于技术创新、售后服务、法规专业知识和伙伴关係模式的综合作用。领先的供应商透过提供能够最大限度减少人工操作、支援封闭式工作流程的平台，以及整合增强可追溯性和批次文件记录的软体来脱颖而出。设备製造商与临床试验机构或合约开发商之间的策略合作十分普遍，这有助于进行实际验证和迭代产品改进。

为供应商和临床领导者提供可操作的建议，以透过互通性、验证一致性和供应弹性来加速安全且可扩展的部署。

产业领导者应优先采取以下几项切实可行的措施来加速产品推广应用，同时管控风险。首先，使产品开发蓝图与当前监管要求中关于流程控制和可追溯性的规定保持一致，将减轻下游合格的负担，并缩短临床试验中心和契约製造的部署时间。其次，投资硬体和软体的模组化和互通性，将使平台能够支援多种治疗模式并整合到不同的临床试验环境中，从而提升长期价值。

采用综合混合方法研究途径，结合对关键相关人员的访谈、技术文件的审查、监管指导的分析以及营运实践的案例研究。

本分析采用多维度研究方法，结合一手访谈、供应商产品文件、监管指南审查和营运案例研究，确保提供平衡且实用的见解。一手访谈对象涵盖广泛的相关人员，包括临床生产经理、製程工程师、采购经理和法规遵循专家，从而获得关于决策标准和实施挑战的实地观点。此外，还对供应商文件和技术规格进行了深入审查，以评估平台架构、耗材生态系统和软体功能。

总结了为什么检验、封闭和自动化的工作流程对于创建更安全、更可靠、运作永续的细胞治疗项目至关重要。

总之，自动化封闭式细胞治疗处理系统的成熟为提高治疗一致性、降低污染风险以及扩大先进细胞疗法的临床应用提供了关键机会。随着技术的进步，最成功的机构将优先考虑经过验证的流程控制、可互操作系统以及强大的服务生态系统。区域差异和贸易政策趋势凸显了灵活筹资策略和在地化支援对于维持专案连续性的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：自动化和封闭式细胞治疗处理系统市场：依产品类型划分

  • 自动化系统
  • 封闭式系统

第九章：自动化和封闭式细胞治疗处理系统市场：依技术划分

  • 离心分离
    • 密度梯度离心
    • 固定角离心分离
    • 摆动斗式离心分离
  • 过滤
    • 微过滤
    • 超过滤
  • 磁选
    • 免疫磁珠分离
    • 顺磁分离

第十章：按製程类型分類的自动化和封闭式细胞治疗处理系统市场

  • 细胞计数和分析
    • 自动计数
    • 人工计数
  • 细胞分离
    • 离心分离
    • 过滤和分离
    • 磁选
  • 细胞製备
  • 细胞保存
  • 细胞洗涤

第十一章：自动化封闭式细胞治疗处理系统市场：依应用领域划分

  • 同种
    • 造血干细胞疗法
    • 自然杀手细胞疗法
  • 自有住房
    • CAR-T细胞疗法
    • 间质干细胞疗法

第十二章：自动化封闭式细胞治疗处理系统市场：依最终使用者划分

  • 合约研究机构
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构

第十三章：自动化封闭式细胞治疗处理系统市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：自动化封闭式细胞治疗处理系统市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：自动化封闭式细胞治疗处理系统市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国自动化封闭式细胞治疗处理系统市场

第十七章：中国自动化封闭式细胞治疗处理系统市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bio-Techne Corporation
  • BioLife Solutions Inc.
  • BioSpherix, Ltd.
  • Cellares Inc.
  • Corning Incorporated
  • Cytiva
  • Danaher Corporation
  • Fresenius SE & Co. KGaA
  • General Electric Company
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Regeneus Ltd.
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Terumo Corporation
  • Thermo Fisher Scientific, Inc.
  • Thermogenesis Holdings, Inc.
Product Code: MRR-3A2E844FE4D9

The Automated & Closed Cell Therapy Processing Systems Market was valued at USD 1.24 billion in 2025 and is projected to grow to USD 1.43 billion in 2026, with a CAGR of 16.49%, reaching USD 3.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.24 billion
Estimated Year [2026] USD 1.43 billion
Forecast Year [2032] USD 3.63 billion
CAGR (%) 16.49%

A concise contextual introduction framing how automation and closed processing are reshaping cell therapy operations, regulatory expectations, and clinical readiness

The therapeutic landscape for cellular medicine is evolving rapidly as automated and closed processing solutions move from niche laboratory tools to foundational infrastructure for clinical programs. Advances in platform engineering, coupled with increased demand for consistent product quality and reduced manual handling, have elevated automated systems and closed systems from operational conveniences to strategic enablers of scalable therapies. Clinicians and manufacturing leaders increasingly view process standardization, contamination control, and traceability as nonnegotiable attributes when planning cell therapy pipelines.

Moreover, regulatory agencies worldwide continue to stress the importance of validated processes and robust documentation, which favors technologies that inherently support reproducibility and auditability. In parallel, technology vendors are investing in modular designs and interoperable software ecosystems to accommodate diverse cell types and evolving protocols. This convergence of clinical, regulatory, and engineering priorities is encouraging adoption across both autologous and allogeneic workflows.

Consequently, stakeholders ranging from research institutes to commercial developers must reassess their operations to incorporate closed and automated solutions earlier in the product lifecycle. This introductory analysis frames the critical drivers, common barriers, and decision criteria that influence selection and deployment of processing technologies, establishing the context for deeper segmentation and regional considerations presented in subsequent sections.

Mapping the major systemic shifts in cell therapy processing that prioritize automation, contamination control, interoperability, and long-term clinical scalability

The last several years have witnessed transformative shifts in the cell therapy ecosystem as the priorities of developers, regulators, and payers converge on reliability, scalability, and patient safety. First, there is a growing emphasis on reducing variability through automation; manual hand-offs and open handling are increasingly viewed as sources of risk that can undermine potency and consistency. Second, closed processing architectures are gaining prominence because they provide stronger contamination control and improve traceability across complex supply chains.

At the same time, advances in separation and enrichment technologies have expanded the range of feasible cell modalities, enabling more precise selection and conditioning of target cell populations. These technical improvements are accompanied by a maturing regulatory dialogue that rewards documented process control and integrated quality systems. Financing patterns and partnerships are also shifting, with contract developers and manufacturers evaluating capital allocation toward flexible automated platforms that support multiple product formats.

Transitioning from proof-of-concept to routine clinical manufacture requires addressing workforce competencies, facility design, and interoperability between instruments and informatics systems. As a result, organizations that invest early in validated automation standards and closed workflows position themselves to accelerate clinical throughput while mitigating operational risk. This section maps those systemic changes and explains why they are likely to persist as foundational trends.

Evaluating how recent tariff changes and trade policy dynamics are reshaping supplier strategies, procurement risk management, and regional supply chain resilience

Recent policy decisions affecting tariffs and trade can materially influence capital expenditure planning and supplier strategies for processing equipment sourced globally. Tariff adjustments alter the relative cost competitiveness of imported instruments and consumables, which in turn affects procurement decisions for both early-stage developers and established manufacturers. Equipment vendors are consequently reassessing manufacturing footprints, supplier contracts, and component sourcing to reduce exposure to cross-border tax changes.

For developers and contract manufacturers, tariffs create an incentive to increase local sourcing of critical components and to negotiate longer-term supply agreements that hedge against future policy swings. This trend is accelerating conversations about regionalization of supply chains and the potential need for duplicated inventories to maintain uninterrupted production during periods of trade uncertainty. In parallel, vendors are responding by investing in localized assembly, modular design that accommodates alternate components, and expanded service networks to preserve competitiveness.

Operationally, the indirect effects of tariff shifts-such as delays in equipment deployment, increased lead times for validated consumables, and higher qualification costs for alternative parts-can slow technology adoption. Therefore, procurement and program managers are advised to incorporate tariff sensitivity into procurement risk assessments and supplier qualification plans. Doing so supports continuity of clinical programs and reduces the likelihood of process disruptions tied to trade policy volatility.

Detailed segmentation analysis showing how product types, clinical applications, separation technologies, end users, and discrete process functions determine procurement and validation priorities

A robust segmentation perspective clarifies how different product architectures, clinical applications, separation technologies, end users, and process types influence procurement decisions and operational priorities. Product type distinguishes between fully automated systems that integrate multiple unit operations and closed systems designed primarily to reduce contamination risk and manual exposure, each presenting distinct validation pathways and facility requirements. Application segmentation separates allogeneic approaches-which include hematopoietic stem cell therapy, mesenchymal stem cell therapy, and natural killer cell therapy-from autologous approaches such as CAR T cell therapy, hematopoietic stem cell therapy, and mesenchymal stem cell therapy, with each application imposing unique throughput, sterility, and chain-of-custody demands.

Technology distinctions matter because centrifugation methods, including density gradient, fixed angle, and swing-bucket variants, deliver different trade-offs in recovery and throughput, while filtration options such as microfiltration and ultrafiltration offer alternate profiles for cell concentration and media exchange. Magnetic separation technologies, whether immunomagnetic bead-based or paramagnetic approaches, provide high-specificity enrichment but require tailored reagent workflows and regulatory control strategies. End users span contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes, each with divergent procurement cycles, validation capabilities, and tolerance for capital intensity.

Process-type segmentation further refines decision-making: cell counting and analysis operations range from automated counters to manual methods; cell preparation activities include formulation and thawing protocols; separation processes encompass centrifugation, filtration, and magnetic separation; storage solutions address long-term and short-term requirements; and washing operations can be automated or manual. Understanding these layered segment distinctions enables stakeholders to align technology choices with clinical objectives, operational capacity, and regulatory obligations.

Regional dynamics and deployment strategies that explain how Americas, Europe Middle East & Africa, and Asia-Pacific markets influence vendor approaches and clinical adoption

Regional dynamics shape adoption pathways, supplier strategies, and regulatory expectations in distinctive ways. In the Americas, innovators and established manufacturers coexist within a regulatory environment that emphasizes evidence of process control and clinical safety, encouraging early adoption of systems that simplify compliance and accelerate hospital-based manufacturing. Funding environments and a concentration of clinical centers of excellence also support partnerships between instrument vendors and clinical developers.

Across Europe, the Middle East & Africa, regulatory frameworks and reimbursement ecosystems vary widely, leading vendors to prioritize flexible, modular platforms that can be adapted to local requirements and clinical practice patterns. Capacity constraints in certain countries drive demand for contract manufacturing and service-based models, while larger markets seek integrated solutions that align with regional GMP expectations. In the Asia-Pacific region, rapid expansion of biotech hubs, ambitious national initiatives to build domestic manufacturing capability, and increasing investments in cell therapy clinical trials create strong demand for both cost-effective closed systems and high-throughput automated platforms. Local suppliers and multinational companies compete to offer solutions that align with regional labor dynamics and infrastructure maturity.

Taken together, these geographic differences encourage suppliers to adopt differentiated market strategies: emphasizing localized service and regulatory support in some areas, while promoting scalability and interoperability in others. Companies that tailor product features and commercial approaches to these regional nuances can better support deployment and long-term program sustainability.

Competitive dynamics and vendor differentiation driven by technological innovation, validation services, consumable strategies, and strategic clinical partnerships

Competitive positioning in the processing systems landscape is driven by a combination of technological innovation, after-sales service, regulatory expertise, and partnership models. Leading suppliers differentiate by offering platforms that minimize manual steps and support closed workflows, while also integrating software that enhances traceability and batch documentation. Strategic collaborations between equipment manufacturers and clinical sites or contract developers are common, enabling real-world validation and iterative product improvement.

Service capabilities, including on-site qualification, validation support, and spare-parts logistics, are often decisive factors for procurement committees, particularly for facilities lacking in-house engineering resources. In addition, providers that offer consumable suites and reagent standardization reduce the complexity of qualification and lower the barrier to adoption for resource-constrained end users. Intellectual property around proprietary separation technologies, cartridge designs, and reagent chemistries can create durable differentiation, but such advantages require clear clinical benefit and regulatory alignment to be impactful.

Finally, newer entrants compete by emphasizing affordability, modularity, and open integration with third-party informatics, whereas incumbent vendors leverage established customer bases and regulatory credentials. The competitive landscape rewards organizations that can demonstrate validated performance across diverse cell types, scalable workflows, and comprehensive technical support.

Actionable recommendations for vendors and clinical leaders to accelerate safe, scalable adoption through interoperability, validation alignment, and supply resilience

Industry leaders should prioritize several actionable steps to accelerate adoption while managing risk. First, aligning product development roadmaps with prevailing regulatory expectations for process control and traceability will reduce downstream qualification burdens and improve time-to-deployment at clinical sites and contract manufacturers. Second, investing in modularity and interoperability-both in hardware and software-allows platforms to serve multiple modalities and to integrate into heterogeneous facility environments, thereby increasing long-term value.

Third, expanding localized service networks and establishing regional assembly or component sourcing can mitigate exposure to tariff fluctuations and supply-chain disruptions, while also shortening lead times for critical spares and qualifications. Fourth, vendors and end users should jointly develop standardized validation protocols and interoperable data formats to streamline technology transfer and accelerate adoption across diverse end-user profiles. Fifth, building flexible commercial models that combine capital equipment with consumable subscriptions or outcome-aligned service agreements can lower initial barriers for hospitals and smaller research centers.

Taken together, these recommendations encourage a balanced approach that marries technological excellence with pragmatic operational safeguards, ultimately enabling more reliable and scalable cell therapy manufacturing across the clinical ecosystem.

Comprehensive mixed-method research approach integrating primary stakeholder interviews, technical documentation review, regulatory guidance analysis, and operational case studies

This analysis draws on a multi-method research approach combining primary interviews, vendor product documentation, regulatory guidance review, and operational case studies to ensure balanced and practical insights. Primary interviews were conducted with a cross-section of stakeholders including clinical manufacturing leads, process engineers, procurement managers, and regulatory affairs specialists, enabling a grounded view of decision criteria and implementation challenges. Vendor literature and technical specifications were reviewed to assess platform architectures, consumable ecosystems, and software capabilities.

Regulatory guidance documents and public policy announcements were examined to identify compliance trends and documentation expectations relevant to closed and automated processing systems. Operational case studies provided context on facility design, validation workflows, and human factors considerations, illustrating how technologies perform in near-production environments. Where possible, anonymized examples of technology transfer and qualification timelines were synthesized to highlight common bottlenecks and mitigation strategies.

Throughout the research, findings were triangulated to reduce bias and ensure that product claims align with observed operational realities. The methodology emphasizes practical applicability, enabling decision-makers to translate insights into procurement specifications, validation plans, and strategic roadmaps.

Concluding synthesis on why validated closed and automated workflows are essential to deliver safer, more reliable, and operationally sustainable cell therapy programs

In summary, the maturation of automated and closed cell therapy processing systems represents a pivotal opportunity to improve consistency, reduce contamination risk, and enable broader clinical access to advanced cellular medicines. As technologies evolve, the most successful organizations will be those that prioritize validated process control, interoperable systems, and robust service ecosystems. Regional differences and trade policy dynamics underscore the need for flexible sourcing strategies and localized support to maintain program continuity.

Stakeholders should therefore adopt a holistic perspective that considers not only device performance but also validation burden, consumable ecosystems, and supplier resilience. By aligning procurement decisions with regulatory expectations and operational realities, clinical developers and manufacturers can reduce risk and accelerate the translation of promising therapies into routine care. Ultimately, the integration of automation and closed processing into development and manufacturing pathways will be a decisive factor in delivering reliable, safe, and scalable cell therapies to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated & Closed Cell Therapy Processing Systems Market, by Product Type

  • 8.1. Automated Systems
  • 8.2. Closed Systems

9. Automated & Closed Cell Therapy Processing Systems Market, by Technology

  • 9.1. Centrifugation
    • 9.1.1. Density Gradient Centrifugation
    • 9.1.2. Fixed Angle Centrifugation
    • 9.1.3. Swing Bucket Centrifugation
  • 9.2. Filtration
    • 9.2.1. Microfiltration
    • 9.2.2. Ultrafiltration
  • 9.3. Magnetic Separation
    • 9.3.1. Immunomagnetic Bead Separation
    • 9.3.2. Paramagnetic Separation

10. Automated & Closed Cell Therapy Processing Systems Market, by Process Type

  • 10.1. Cell Counting & Analysis
    • 10.1.1. Automated Counting
    • 10.1.2. Manual Counting
  • 10.2. Cell Separation
    • 10.2.1. Centrifugation Separation
    • 10.2.2. Filtration Separation
    • 10.2.3. Magnetic Separation
  • 10.3. Cell Preparation
  • 10.4. Cell Storage
  • 10.5. Cell Washing

11. Automated & Closed Cell Therapy Processing Systems Market, by Application

  • 11.1. Allogeneic
    • 11.1.1. Hematopoietic Stem Cell Therapy
    • 11.1.2. Natural Killer Cell Therapy
  • 11.2. Autologous
    • 11.2.1. Car T Cell Therapy
    • 11.2.2. Mesenchymal Stem Cell Therapy

12. Automated & Closed Cell Therapy Processing Systems Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotech Companies
  • 12.4. Research Institutes

13. Automated & Closed Cell Therapy Processing Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automated & Closed Cell Therapy Processing Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automated & Closed Cell Therapy Processing Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automated & Closed Cell Therapy Processing Systems Market

17. China Automated & Closed Cell Therapy Processing Systems Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bio-Techne Corporation
  • 18.6. BioLife Solutions Inc.
  • 18.7. BioSpherix, Ltd.
  • 18.8. Cellares Inc.
  • 18.9. Corning Incorporated
  • 18.10. Cytiva
  • 18.11. Danaher Corporation
  • 18.12. Fresenius SE & Co. KGaA
  • 18.13. General Electric Company
  • 18.14. Lonza Group AG
  • 18.15. Merck KGaA
  • 18.16. Miltenyi Biotec B.V. & Co. KG
  • 18.17. Novartis AG
  • 18.18. Pluristem Therapeutics Inc.
  • 18.19. Regeneus Ltd.
  • 18.20. Sartorius AG
  • 18.21. STEMCELL Technologies Canada Inc.
  • 18.22. Terumo Corporation
  • 18.23. Thermo Fisher Scientific, Inc.
  • 18.24. Thermogenesis Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY DENSITY GRADIENT CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY DENSITY GRADIENT CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY DENSITY GRADIENT CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FIXED ANGLE CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FIXED ANGLE CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FIXED ANGLE CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SWING BUCKET CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SWING BUCKET CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SWING BUCKET CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MICROFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MICROFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MICROFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ULTRAFILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ULTRAFILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ULTRAFILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY IMMUNOMAGNETIC BEAD SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY IMMUNOMAGNETIC BEAD SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY IMMUNOMAGNETIC BEAD SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PARAMAGNETIC SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PARAMAGNETIC SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PARAMAGNETIC SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED COUNTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED COUNTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOMATED COUNTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MANUAL COUNTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MANUAL COUNTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MANUAL COUNTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL WASHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL WASHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL WASHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 233. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 235. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PROCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL COUNTING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 240. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY CENTRIFUGATION, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY FILTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION AUTOMATED & CLOSED CELL THERAPY PROCESSING SYSTEMS MARKET SIZE, BY MAGNETIC SEPARATI